

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/807,635
		Filing Date	March 23, 2004
		First Named Inventor	Daniel E. AFAR
		Art Unit	1642
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	11	Attorney Docket Number	511582001111

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1448 (7 pages) Return Receipt Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
CUSTOMER NO. 36327		


### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP		
Signature			
Printed name	Kate H. Murashige		
Date	March <u>L</u> , 2005	Reg. No.	29,959

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 1, 2005

Signature (Rhea Amid)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 3-1-05

Signature:

(Rhea Amid)

PATENT  
Docket No. 511582001111

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Daniel E. AFAR et al.

Serial No.: 10/807,635

Filing Date: March 23, 2004

For: NOVEL 13-TRANSMEMBRANE  
PROTEIN EXPRESSED IN PROSTATE  
CANCER

Examiner: Not Yet Assigned

Group Art Unit: 1642

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 10/285,045, filed October 30, 2002, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - A fee is required. A check in the amount of \_\_ is enclosed.
  - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_ is enclosed.
  - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 511582001111. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 1, 2005

Respectfully submitted,

By Kate H. Murashige  
Kate H. Murashige  
Registration No.: 29,959  
MORRISON & FOERSTER LLP  
3811 Valley Centre Drive, Suite 500  
San Diego, California 92130  
(858) 720-5112

O I P E  
M A R 0 3 2005  
P A T E N T E D O C U M E N T  
J C 3

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Docket Number 511582001111	Application Number 10/807,635
	Applicant Daniel E. AFAR et al.	
	Filing Date March 23, 2004	Group Art Unit 1642
	Mailing Date: March 1, 2005	

### U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/2002	US2002022248	Xu et al.	435	069.1	
	2.	08/2002	US2002103125	Ashkenazi et al.	514	12	
	3.	08/2002	US2002119130	Eaton et al.	424	94.1	
	4.	09/2002	US2002123463	Ashkenazi et al.	514	12	
	5.	09/2002	US2002127576	Ashkenazi et al.	435	6	
	6.	09/2002	US2002132252	Ashkenazi et al.	435	6	
	7.	10/2002	US2002142961	Ashkenazi et al.	514	12	
	8.	10/2002	US2002160384	Ashkenazi et al.	435	6	
	9.	11/2002	US2002177164	Ashkenazi et al.	435	7.1	
	10.	12/2002	US2002182638	Eaton et al.	435	7.1	
	11.	12/2002	US2002183493	Eaton et al.	530	388.1	
	12.	12/2002	US2002183494	Eaton et al.	530	388.1	
	13.	12/2002	US2002192763	Xu et al.	435	69.7	
	14.	12/2002	US2002193299	Ashkenazi et al.	514	12	
	15.	12/2002	US2002193300	Ashkenazi et al.	514	12	
	16.	12/2002	US2002197615	Ashkenazi et al.	435	6	
	17.	12/2002	US2002198148	Ashkenazi et al.	514	12	
	18.	01/2003	US2003003531	Ashkenazi et al.	435	69.1	
	19.	01/2003	US2003008297	Ashkenazi et al.	435	6	
	20.	01/2003	US2003009012	Eaton et al.	530	388.1	
	21.	01/2003	US2003009013	Eaton et al.	530	388.1	
	22.	01/2003	US2003013855	Eaton et al.	530	388.1	
	23.	01/2003	US2003017476	Ashkenazi et al.	435	6	
	24.	01/2003	US2003017981	Ashkenazi et al.	514	12	
	25.	01/2003	US2003017982	Ashkenazi et al.	514	12	
	26.	01/2003	US2003018168	Eaton et al.	530	350	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>				Docket Number 511582001111	Application Number 10/807,635		
				Applicant		Daniel E. AFAR et al.	
				Filing Date March 23, 2004		Group Art Unit 1642	
				Mailing Date: March <u>1</u> , 2005			

	27.	01/2003	US2003018172	Eaton et al.	530	388.15	
	28.	01/2003	US2003018173	Eaton et al.	530	388.15	
	29.	01/2003	US2003018183	Eaton et al.	536	23.5	
	30.	01/2003	US2003022187	Ashkenazi et al.	435	6	
	31.	01/2003	US2003023042	Eaton et al.	530	388.1	
	32.	02/2003	US2003027162	Ashkenazi et al.	435	6	
	33.	02/2003	US2003027163	Ashkenazi et al.	435	6	
	34.	02/2003	US2003027212	Eaton et al.	435	7.1	
	35.	02/2003	US2003027754	Ashkenazi et al.	514	12	
	36.	02/2003	US2003027985	Ashkenazi et al.	530	350	
	37.	02/2003	US2003027986	Eaton et al.	530	350	
	38.	02/2003	US2003027992	Eaton et al.	530	388.1	
	39.	02/2003	US2003027993	Eaton et al.	530	388.1	
	40.	02/2003	US2003032023	Ashkenazi et al.	435	6	
	41.	02/2003	US2003036634	Eaton et al.	530	350	
	42.	02/2003	US2003040473	Ashkenazi et al.	514	12	
	43.	03/2003	US2003044806	Ashkenazi et al.	435	6	
	44.	03/2003	US2003045463	Ashkenazi et al.	514	12	
	45.	03/2003	US2003045684	Eaton et al.	530	350	
	46.	03/2003	US2003049638	Ashkenazi et al.	435	6	
	47.	03/2003	US2003049681	Ashkenazi et al.	435	7.1	
	48.	03/2003	US2003049682	Ashkenazi et al.	435	7.1	
	49.	03/2003	US2003049735	Eaton et al.	435	69.1	
	50.	03/2003	US2003050462	Eaton et al.	536	23.2	
	51.	03/2003	US2003050465	Eaton et al.	536	23.2	
	52.	03/2003	US2003054359	Ashkenazi et al.	435	6	
	53.	03/2003	US2003054403	Ashkenazi et al.	435	7.1	
	54.	03/2003	US2003054404	Ashkenazi et al.	435	7.1	
	55.	03/2003	US2003054987	Ashkenazi et al.	514	12	
	56.	03/2003	US2003059780	Ashkenazi et al.	435	6	
	57.	03/2003	US2003059782	Ashkenazi et al.	435	6	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>				Docket Number 511582001111	Application Number 10/807,635		
				Applicant			
				Daniel E. AFAR et al.			
				Filing Date March 23, 2004	Group Art Unit 1642		
				Mailing Date: March 1, 2005			

	58.	03/2003	US2003059783	Ashkenazi et al.	435	6	
	59.	03/2003	US2003059831	Ashkenazi et al.	435	7.1	
	60.	03/2003	US2003059832	Ashkenazi et al.	435	7.1	
	61.	03/2003	US2003059833	Ashkenazi et al.	435	7.1	
	62.	03/2003	US2003060407	Ashkenazi et al.	514	12	
	63.	03/2003	US2003060600	Eaton et al.	530	350	
	64.	03/2003	US2003060601	Eaton et al.	530	350	
	65.	03/2003	US2003060602	Eaton et al.	530	350	
	66.	04/2003	US2003064375	Ashkenazi et al.	435	6	
	67.	04/2003	US2003065143	Eaton et al.	530	350	
	68.	04/2003	US2003065161	Eaton et al.	536	23.5	
	69.	04/2003	US2003068623	Ashkenazi et al.	435	6	
	70.	04/2003	US2003068647	Ashkenazi et al.	435	7.1	
	71.	04/2003	US2003069394	Eaton et al.	530	350	
	72.	04/2003	US2003069403	Ashkenazi et al.	536	23.1	
	73.	04/2003	US2003073090	Ashkenazi et al.	435	6	
	74.	04/2003	US2003073623	Drmanac et al.	514	12	
	75.	04/2003	US2003078387	Eaton et al.	530	388.15	
	76.	05/2003	US2003082546	Ashkenazi et al.	435	6	
	77.	05/2003	US2003083461	Ashkenazi et al.	530	350	
	78.	05/2003	US2003083473	Eaton et al.	530	388.15	
	79.	05/2003	US2003087304	Ashkenazi et al.	435	7.1	
	80.	05/2003	US2003087305	Ashkenazi et al.	435	7.1	
	81.	05/2003	US2003099974	Lillie et al.	435	6	

#### FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
	82.	02/1999	WO 99/06548	WIPO				
	83.	02/1999	WO 99/06549	WIPO				
	84.	02/1999	WO 99/06550	WIPO				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Docket Number 511582001111	Application Number 10/807,635	
		Applicant	Daniel E. AFAR et al.	
		Filing Date March 23, 2004	Group Art Unit 1642	
		Mailing Date: March <u>/</u> , 2005		

	85.	08/1999	WO 99/40189	WIPO					
	86.	12/1999	WO 99/63088	WIPO					
	87.	01/2000	WO 00/04149	WIPO					
	88.	10/2000	WO 00/61746	WIPO					
	89.	12/2000	WO 00/73454	WIPO					
	90.	12/2000	WO 00/77021	WIPO					
	91.	03/2001	WO 01/16318	WIPO					
	92.	04/2001	WO 01/25272	WIPO					
	93.	05/2001	WO 01/34802	WIPO					
	94.	06/2001	WO 01/46258	WIPO					
	95.	07/2001	WO 01/51628	WIPO					
	96.	07/2001	WO 01/51633	WIPO					
	97.	07/2001	WO 01/53836	WIPO					
	98.	08/2001	WO 01/57270	WIPO					
	99.	08/2001	WO 01/57271	WIPO					
	100.	08/2001	WO 01/57272	WIPO					
	101.	08/2001	WO 01/57273	WIPO					
	102.	08/2001	WO 01/57274	WIPO					
	103.	08/2001	WO 01/57275	WIPO					
	104.	08/2001	WO 01/57276	WIPO					
	105.	08/2001	WO 01/57277	WIPO					
	106.	08/2001	WO 01/57278	WIPO					
	107.	08/2001	WO 01/60860	WIPO					
	108.	10/2001	WO 01/73027	WIPO					
	109.	10/2001	WO 01/73032	WIPO					
	110.	10/2001	WO 01/75067	WIPO					
	111.	11/2001	WO 01/86003	WIPO					
	112.	11/2001	WO 01/90304	WIPO					
	113.	12/2001	WO 01/96388	WIPO					
	114.	12/2001	WO 01/96390	WIPO					
	115.	02/2002	WO 02/12328	WIPO					

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Docket Number 511582001111	Application Number 10/807,635
		Applicant Daniel E. AFAR et al.	
		Filing Date March 23, 2004	Group Art Unit 1642
		Mailing Date: March <u>1</u> , 2005	

	116.	08/2002	WO 02/58534	WIPO				
	117.	09/2002	WO 02/74961	WIPO				
	118.	10/2002	WO 02/83876	WIPO				
	119.	11/2002	WO 02/89747	WIPO				
	120.	12/2002	WO 02/97031	WIPO				
	121.	09/2000	EP 1033401	Europe				
	122.	02/2001	EP 1074617	Europe				

**OTHER DOCUMENTS***(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	123.	Huang, G.M. et al., "Prostate cancer expression profiling by cDNA sequencing analysis," EMBL Database entry AI557659, Accession Number AI557659, March 25, 1999, EP002144281, & Huang, G.M. et al., Genomics, Volume 59, No. 2, July 1999, pages 178-186.
	124.	NCI-CGAP, "National Cancer Institute, Cancer Genome Anatomy Project (CGAP)", October 7, 1997, EMBL Database Entry AA612666, Accession Number AA612666, XP002144282.
	125.	Rowen, L. et al., "Sequence of the human major histocompatibility complex class III region", March 29, 1999, EMBL Database Entry AF134726, Accession Number AF134726, XP002144283.
	126.	Rowen, L. et al., "Sequence of the human major histocompatibility complex class III region", November 1, 1999, EMBL Database Entry Q9Y332, XP002144284.
	127.	Reiter, Robert E. et al., "Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer", Proc. Natl. Acad. Sci., February 1998, Volume 95, pages 1735-1740, XP-002078363.
	128.	Rowen, L., March 24, 1999, NCBI Accession Number AAD21813.
	129.	Inoko, Hidetoshi, March 30, 2000, NCBI Accession Number AP000502.
	130.	Simpson, A.J.G., March 16, 2000, dbEST Id 4011587, GenBank Acc. AW579065.
	131.	Simpson, A. J. G., March 23, 2000, dbEST Id 4036649, GenBank Acc. AW603383.
	132.	Simpson, A. J. G., March 23, 2000, dbEST Id 4035408, GenBank Acc. AW602142.
	133.	Strausberg, Robert, September 6, 1999, dbEST Id 3075200, GenBank Acc. AI951815.
	134.	Strausberg, Robert, March 9, 2000, dbEST Id 3079479, GenBank Acc. AI956094.
	135.	Strausberg, Robert, June 21, 1999, dbEST ID 2655196, GenBank Acc. AI745450.
	136.	Strausberg, Robert, March 7, 2000, dbEST Id 2893738, GenBank Acc. AI813886.
	137.	Simpson, A.J.G., February 4, 2000, dbEST Id 3787048, GenBank Acc. AW393065.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  <i>(Use several sheets if necessary)</i>		Docket Number 511582001111	Application Number 10/807,635
		Applicant	Daniel E. AFAR et al.
		Filing Date March 23, 2004	Group Art Unit 1642
		Mailing Date: March 1, 2005	

138.	Huang, Guyang Matthew, August 9, 1999, dbEST Id 2373824, GenBank Acc. AI557660.
139.	Strausberg, Robert, August 14, 1997, dbEST Id 1112901, GenBank Acc. AA468365.
140.	Wilson, R. K., June 10, 1999, dbEST Id 2629269, GenBank Acc. AI721101.
141.	Strausberg, Robert, August 21, 1997, dbEST Id 1178186, GenBank Acc. AA533783.
142.	Strausberg, Robert, February 16, 1999, dbEST Id 2101871, GenBank Acc. AI318311.
143.	Strausberg, Robert, October 30, 1999, dbEST Id 3291479, GenBank Acc. AW139432.
144.	Strausberg, Robert, February 24, 2000, dbEST Id 3880006, GenBank Acc. AW469133.
145.	Strausberg, Robert, March 7, 2000, dbEST Id 2947457, GenBank Acc. AI858987.
146.	Strausberg, Robert, May 13, 1999, dbEST Id 2376359, GenBank Acc. AI560195.
147.	Strausberg, Robert, March 7, 2000, dbEST Id 2946846, GenBank Acc. AI858299.
148.	Strausberg, Robert, May 14, 1999, dbEST Id 2390443, GenBank Acc. AI572115.
149.	Strausberg, Robert, May 14, 1999, dbEST Id 2381301, GenBank Acc. AI565097.
150.	Takeda, Jun, September 9, 1997, dbEST Id 1241269, GenBank Acc. C75094.
151.	Wilson, R. K., July 7, 1995, dbEST Id 285541, GenBank Acc. H25030.
152.	Kerlavage, A. R, April 21, 1997, dbEST Id 1008183, GenBank Acc. AA 366876.
153.	Strausberg, Robert, December 14, 1999, dbEST Id 2443929, GenBank Acc. AI625125.
154.	Wilson, R. K., April 20, 1995, dbEST Id 194186, GenBank Acc. R24141.
155.	Strausberg, Robert, March 8, 2000, dbEST Id 3055029, GenBank Acc. AI932443.
156.	Ezzell, Journal of NIH Research (1995) 7:46-49
157.	Spitler, Cancer Biotherapy (1995) 10:1-3
158.	Dulcert et al., Accession No. AAY12282, 1999
159.	McClean and Hill, Eur. J. Cancer (1993) 29A:2243-2248
160.	Fu et al., EMBO Journal (1996) 15:4392-4401
161.	Brennan et al., Journal of Autoimmunity (1989) 2(suppl.):177-186
162.	Zimmer, Cell Motility and the Cytoskeleton (1991) 20:325-337
163.	Ericksson et al., Diabetologia (1992) 35:143-147
164.	Craft et al., Cancer Res. (1999) 59:5030-5036
165.	Kilty and Amara, Curr. Opin. Biotechnology (1992) 3:675-682
166.	Klein et al., Nature Med. (1997) 3:402-408
167.	Morton and Myszka, Methods in Enzymology (1998) 295:268
168.	Muller et al., MCB (1991) 11:1785

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  <i>(Use several sheets if necessary)</i>		Docket Number 511582001111	Application Number 10/807,635
		Applicant	Daniel E. AFAR et al.
		Filing Date March 23, 2004	Group Art Unit 1642
		Mailing Date: March 7, 2005	

	169.	Pemberton et al., J. of Histochemistry and Cytochemistry (1997) 45:1697-1706
	170.	Storrie et al., Methods Enzymol. (1990) 182:203-225
	171.	Welch et al., Int. J. Cancer (1989) 43:449-457
	172.	Welford, Opt. Quant. Elect. (1991) 23:1

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	